DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Treatment of Supine Hypertension in Autonomic Failure

Information source: Vanderbilt University
ClinicalTrials.gov processed this data on November 27, 2014
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Clonidine (Drug); Nitroglycerin transdermal (Drug); Dipyridamole/ Aspirin (Aggrenox) (Drug); Desmopressin (DDAVP) (Drug); Sildenafil (Drug); Nifedipine (Drug); Hydralazine (Drug); Hydrochlorothiazide (Drug); Placebo (Drug); Bosentan (Drug); Diltiazem (Drug); Eplerenone (Drug); guanfacine (Drug); L-arginine (Dietary Supplement); captopril (Drug); carbidopa (Drug); losartan (Drug); metoprolol tartrate (Drug); nebivolol hydrochloride (Drug); prazosin hydrochloride (Drug); tamsulosin hydrochloride (Drug); Head-up tilt. (Other); aliskiren (Drug); Local heat stress (Other)

Phase: Phase 1/Phase 2

Status: Recruiting

Sponsored by: Vanderbilt University

Official(s) and/or principal investigator(s):
Italo Biaggioni, MD, Principal Investigator, Affiliation: Vanderbilt University

Overall contact:
Bonnie Black, RN, Email: adcresearch@vanderbilt.edu

Summary

Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0. 3 ± 0. 05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0. 0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.

Clinical Details

Official title: The Pathophysiology and Treatment of Supine Hypertension in Patients With Autonomic Failure

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Decrease in supine systolic blood pressure

Secondary outcome: Decrease in pressure natriuresis

Detailed description: 1. Overnight Medication Trials: Patients will be studied on the GCRC while in 150 mEq/day sodium balance and on a diet free of substances which interfere with catecholamine determination. Subjects will be asked to use the bathroom to empty their bladder at 8: 00 PM. They will be given a randomly chosen medication aliskiren (Tekturna) 150-300mg po, bosentan (Tracleer) 62. 5

- 125 mg po, captopril 25-50mg po, carbidopa 25-200mg po, clonidine 0. 1-0. 2mg po,

desmopressin 0. 2 - 0. 6mg po (DDAVP), -diltiazem 30-60 mg po, dipyridamole 200 mg and

aspirin 25 mg po (Aggrenox), eplerenone (Inspra) 50-100 mg po, guanfacine (Tenex) 1-3 mg po, hydralazine 10-50 mg po, hydrochlorothiazide 12. 5-100 mg po, L- arginine 6-17 g po, losartan 25-100mg po, metoprolol tartrate (Lopressor) 25-100 mg po, nebivolol hydrochloride (Bystolic) 2. 5-40 mg po, nitroglycerin-transdermal 0. 05-0. 2 mg patch, nifedipine (adalat) doses 10-30 mg, prazosin hydrochloride 0. 5-1 mg po, sildenafil (Viagra) 25- 100 mg po, tamsulosin hydrochloride (Flomax) 0. 4-0. 8 mg po. The combination desmopressin 0. 2 mg po (DDAVP) and nitroglycerin-transdermal 0. 05-0. 2 mg. The combinations desmopressin 0. 2 mg po and nifedipine (10-30 mg). A placebo pill or skin patch will be done as a control to measure their supine blood pressure without medication intervention. They will then be asked to lie down with the head of the bed elevated 10 degrees. An automated blood pressure cuff (Dinamap) will be wrapped around an upper arm and blood pressure will be measured automatically 2 times in a row every 2 hours. At 8 AM the following morning the study ends. The subjects will then stand at the bedside as motionless as possible for 30 minutes for blood pressure and heart rate determination. Urine will be collected for 24 hours for determination of volume and sodium, potassium and catecholamines (for some medication trials) in 12 hour segments, from 8 a. m. to 8 p. m. and 8 p. m. to 8 a. m. to ascertain how the medications affect urine production. For medication trials affecting renal Na and/or water regulation (e. g. desmopressin, carbidopa), blood samples will be collected (5 mL, 1 teaspoon) at 8 PM and 8 AM for determination of a basic metabolic panel. Raising the head of the bed during the night is a non-pharmacologic measure that may reduce supine blood pressure, nocturnal natriuresis and improve orthostatic hypotension the following morning in autonomic failure patients with supine hypertension. However, it is not known if tilting the bed with the head up is better than raising only the head of the bed. To compare the effect of these two ways of raising the head of the bed on nighttime blood pressure and nocturnal natriuresis, some patients will undergo two additional tests. On two separate nights (either consecutive or not), patients will receive the placebo and will be assigned by simple randomization to lie down in one of two different bed positions: 1. The head of the bed elevated 10 degrees (~ 7 inches); or 2. The whole bed tilted head-up 5 degrees in reverse trendelenburg (head of the bed elevated ~7 inches). Blood pressure, orthostatic tolerance at 8 AM and urine collections will be performed as described above. 2. Blood Pressure Lowering Effect of Local Heat Stress in Supine Hypertension: Heat stress due to high environmental temperatures lowers blood pressure in autonomic failure patients. The mechanisms underlying this phenomenon are not fully understood but it could be associated with 2 factors: First, heart stress is more likely to increase core temperature in this patient population because heat dissipation is impaired due to inability to sweat. Second, autonomic failure patients lack the compensatory sympathetic splanchnic vasoconstriction and tachycardia that normally maintain blood pressure in response to heat stress in healthy subjects. We hypothesize, therefore, that even moderate levels of local heat stress will lower blood pressure in patients with autonomic failure and supine hypertension. We propose a pilot study to evaluate the effect of local (abdominal) heat stress on blood pressure in autonomic failure patients, something that has not been previously done, and to assess its potential use in the treatment of supine hypertension This pilot study is optional and will be conducted in patients already enrolled in the "Evaluation and Treatment of Autonomic Failure" and the medication trial part of this protocol. Subjects will be studied in the supine position on two study days (with and without heat stress). Each study day will last ~3 hours. Core body and skin temperature will be monitored throughout the study using an ingestible telemetry pill and dermal patches. Blood pressure and heart rate will be measured intermittently with an automated blood pressure sphygmomanometer wrapped around an upper arm. Segmental body fluid shifts will be estimated using bioelectrical Impedance and hemodynamic parameters using body impedance and the rebreathing test (Innocor). After obtaining normothermic baseline measurements, we apply passive heat-stress with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at ~44ºC continuously for 2 hr. Outcome measurements are obtained at 1 and 2 hours after passive heat-stress, or when the CBT increases ~1ºC above baseline, whichever occurs first. For the control (non-heating) study day, the heating pad will be applied on patients but we will not turn it on, and data collection will be performed at the one-hour intervals for 2 hours, to provide a time control. 3. Circadian Hemodynamic Changes in Autonomic Failure Patients with Supine Hypertension: This study is optional and will be conducted in patients already enrolled in the "Evaluation and Treatment of Autonomic Failure" and the medication trial part of this protocol. A separate consent form (addendum) will be provided. In the present study, we propose the following: 1. Monitor BP and HR in patients with AF and supine hypertension during a 24-hour period, which includes fixed periods of supine rest during the day, with strict control of physical activities, meals, water ingestion and other confounding factors. This will allow us to learn more about the intrinsic circadian variation of BP in our patients without the influence of "external factors". 2. Characterize the hemodynamic changes underlying the dipping phenomenon and the morning BP surge, and 3. Assess changes in plasma volume (measured by changes in hematocrit), calculated plasma osmolality and hormones that regulate blood pressure and blood volume, in order to learn more about the mechanisms responsible for the dipping phenomenon and morning BP surge in autonomic failure patients with supine hypertension. These parameters will be compared with the circadian rhythm of body temperature, a marker of the central circadian rhythm, to determine whether these diurnal changes are synchronized to the circadian pacemaker. The duration of the study day will be 24 hours and can start any time during the day. Typically, the study will start ~ 8AM. Therapeutic trials for orthostatic hypotension and/or supine hypertension as well as other study procedures related to the above mentioned protocols may be performed while participating in this study. If an overnight medication trial is performed during the study, patients may be offered to participate in a second study day without any medication.

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with autonomic failure and with supine hypertension from all races

Exclusion Criteria:

- All medical students

- Pregnant women

- High-risk patients (e. g. heart failure, symptomatic coronary artery disease, liver

impairment, history of stroke or myocardial infarction)

- History of serious allergies or asthma.

Locations and Contacts

Bonnie Black, RN, Email: adcresearch@vanderbilt.edu

Vanderbilt University, Nashville, Tennessee 37232, United States; Recruiting
Bonnie Black, RN, Email: adcresearch@vanderbilt.edu
Italo Biaggioni, MD, Principal Investigator
David Robertson, MD, Sub-Investigator
Satish Raj, MD, Sub-Investigator
Alfredo Gamboa, MD, Sub-Investigator
Cyndya Shibao, MD, Sub-Investigator
Andre Diedrich, MD, Sub-Investigator
Luis E Okamoto, MD, Sub-Investigator
Amy C Arnold, PhD, Sub-Investigator
Cindy A Dorminy, MEd, LPN, Sub-Investigator
Additional Information

Autonomic Dysfunction Center Website

Related publications:

Shibao C, Okamoto L, Biaggioni I. Pharmacotherapy of autonomic failure. Pharmacol Ther. 2012 Jun;134(3):279-86. doi: 10.1016/j.pharmthera.2011.05.009. Epub 2011 Jun 12. Review.

Starting date: June 2001
Last updated: September 24, 2014

Page last updated: November 27, 2014

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014